4 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Withdrawn 4 |
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma Leflunomide, Quality-of-Life Assessment, Questionnaire Administration - Smoldering Plasma Cell Myeloma | Phase 2 | Withdrawn | City of Hope Medical Center | 2019-12-11 | 2019-11-14 | |
| Imaging Studies and the Development of Multiple Myeloma Fluciclatide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2012-03-27 | 2019-12-16 | |
| Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma Simvastatin - Smoldering Multiple Myeloma | Phase 2 | Withdrawn | Meir Medical Center | 2007-09-01 | 2015-04-16 |
Smoldering Multiple Myeloma (3) · Monoclonal Gammopathy of Undetermined Significance (2) · Multiple Myeloma (1) · Peripheral Nervous System Diseases (1)
Blood Protein Disorders (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Paraproteinemias (4) · Neoplasms (3) · Precancerous Conditions (3) · Cardiovascular Diseases (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Lymphoproliferative Disorders (1) · Neoplasms by Histologic Type (1) · Neoplasms, Plasma Cell (1)
AH 111585 (1) · Leflunomide (1) · Simvastatin (1) · daratumumab (1)
City of Hope Medical Center (1) · Georgetown University (1) · Meir Medical Center (1) · National Cancer Institute (NCI) (1)
United States (2)
Carl O Landgren, M.D. (1) · Kimberley Doucette, MD (1) · Michael Lishner, MD (1) · Michael Rosenzweig (1)